Neuronetics Announces Aetna Policy Update Expands TMS Availability For Adolescents With Depression
Neuronetics Announces Aetna Policy Update Expands TMS Availability For Adolescents With Depression
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Aetna has updated its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with MDD (major depressive disorder). This expanded access follows the recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS as the first and only TMS treatment cleared as a first-line add-on for adolescents aged 15-21.
醫療科技公司Neuronetics, Inc.(納斯達克:STIM)專注於設計、開發和推銷改善神經健康障礙患者生活質量的產品。公司宣佈Aetna已經更新了TMS(經顱磁刺激)保險覆蓋範圍,將包括15歲及以上患有MDD(重度抑鬱障礙)的青少年。這個擴大的範圍是在美國食品和藥物管理局(FDA)最近覈准NeuroStar TMS作爲唯一一種作爲15-21歲青少年的一線附加治療的經顱磁刺激的情況下進行的。
The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications. Aetna is one of the largest health plans in the country with over 19.4 million lives covered through its commercial policies nationwide. The TMS policy update is effective immediately.
覆蓋標準規定TMS治療必須依照FDA標示適應症,採用FDA認證設備。Aetna是全美最大的健康保險計劃之一,在全國範圍內通過其商業政策覆蓋着1940萬人的生活。TMS政策的更新立即生效。
譯文內容由第三人軟體翻譯。